✦ LIBER ✦

Malignant melanoma and renal cell carcinoma: Immunological and haematological effects of recombinant human interleukin-2

✍ Scribed by Khizar Hayat; Sheila Rodgers; Lesley Bruce; Robert C. Rees; Karen Chapman; Steve Reeder; Mark S. Dorreen; Eamonn Sheridan; Thiagarajan Sreenivasan; Barry W. Hancock

Book ID: 119156992
Publisher: Elsevier Science
Year: 1991
Weight: 809 KB
Volume: 27
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(91)90270-n

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase-II study of low-dose cyclophosph

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

✍ Albrecht Lindemann; Klaus Höffken; Reinhold E. Schmidt; Volker Diehl; Otto Kloke 📂 Article 📅 1989 🏛 Springer-Verlag 🌐 English ⚖ 937 KB

Treatment of malignant melanoma and rena

Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants

✍ McIntyre, Catherine A.; Chapman, Karen; Reeder, Steve; Dorreen, Mark S.; Bruce, 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 804 KB

A combination of subcutaneous recombinan

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma

✍ Vuoristo, Merisisko; Jantunen, Ismo; Pyrhönen, Seppo; Muhonen, Timo; Kellokumpu- 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 410 KB

A phase I study of recombinant human int

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

Polyethylene glycol conjugated interleuk

Polyethylene glycol conjugated interleukin-2: Clinical and immunologic effects in patients with advanced renal cell carcinoma

✍ Ronald M. Bukowski; James Young; Gary Goodman; Frederick Meyers; Brian F. Issell 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 487 KB

Continuous infusion recombinant interleu

Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies

✍ West, W.H. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 491 KB